We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Troponin Testing Presents Problems in Kidney-Impaired People

By LabMedica International staff writers
Posted on 24 Jun 2021
Print article
Image: ARCHITECT STAT High Sensitivity Troponin-I blood test (Photo courtesy of Abbott Laboratories)
Image: ARCHITECT STAT High Sensitivity Troponin-I blood test (Photo courtesy of Abbott Laboratories)
High-sensitivity cardiac troponin (hs-cTn) assays have improved the diagnosis of myocardial infarction in patients with healthy kidney function and are now widely used in clinical practice.

However, in patients with kidney impairment, long-term elevations in troponin levels are common, and interpretation can be more challenging. As such, the effect of implementing hs-cTn testing on the diagnosis and outcomes of patients with kidney impairment is uncertain.

Medical Scientists at the University of Edinburgh (Edinburgh, Scotland) and their colleagues evaluated the use of a hs-cTnI assay in consecutive patients with suspected acute coronary syndrome across 10 hospitals in a stepped-wedge, cluster-randomized clinical trial of 46,927 consecutive patients. Throughout the trial, cTnI was measured using contemporary and high-sensitivity assays the ARCHITECTSTAT, Abbott Laboratories, Abbott Park, IL, USA). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Kidney impairment was defined as an eGFR of less than 60 mL/min/1.73 m2.

The team reported that overall, hs-cTnI concentrations were elevated in 10,111 patients (22%), of whom 42% had kidney impairment. These newer assays flagged six fold more patients as kidney function declined from an eGFR of at least 90 to less than 30 mL/min/1.73 m2 (10% versus 66%). However, the proportion with acute type 1 myocardial infarction (MI) dropped precipitously across that same range of renal function, from 74% to 35%.

In addition, the increase in identification did not correlate with better outcomes. Subsequent type 1 or 4b (more than 24 hours after percutaneous coronary intervention) MI or cardiovascular death were equally common at one year for patients treated before and after clinical use of the high-sensitivity test both with kidney impairment (25% versus 24%; adjusted hazard ratio [HR] = 1.00) and without it (13% versus 11%; adjusted HR = 0.89).

Patients reclassified as having elevated troponin with the more sensitive versus conventional assay also did not have better outcomes. Nicholas L. Mills, MD, a consultant cardiologist and senior author of the study said, “The reasons for this are complex. Two-thirds of patients with kidney impairment and elevated hs-cTnI concentrations had a diagnosis other than type 1 myocardial infarction. In the absence of evidence from randomized trials, there is little guidance to inform clinical decisions for this heterogeneous group.” The study was published on June 7, 2021, in the journal JAMA Internal Medicine.

Related Links:
University of Edinburgh
Abbott Laboratories


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.